[go: up one dir, main page]

PA8684501A1 - Formulaciones de estrogenos conjugados y bazedoxifeno - Google Patents

Formulaciones de estrogenos conjugados y bazedoxifeno

Info

Publication number
PA8684501A1
PA8684501A1 PA20068684501A PA8684501A PA8684501A1 PA 8684501 A1 PA8684501 A1 PA 8684501A1 PA 20068684501 A PA20068684501 A PA 20068684501A PA 8684501 A PA8684501 A PA 8684501A PA 8684501 A1 PA8684501 A1 PA 8684501A1
Authority
PA
Panama
Prior art keywords
bazedoxifen
strogens
conjugated
formulations
salt
Prior art date
Application number
PA20068684501A
Other languages
English (en)
Inventor
Arwinder Nagi
Ramarao S Chatlapalli
Pelt Lawrence Van
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37401610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8684501(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8684501A1 publication Critical patent/PA8684501A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

LA PRESENTE INVENCIÓN TIENE RELACIÓN CON FORMULACIONES DE DOSIFICACIÓN SÓLIDAS CONTENIENDO ESTRÓGENOS CONJUGADOS Y BAZEDOXIFENO, O UNA SAL DE ELLOS. EN ALGUNAS MODALIDADES LAS COMPOSICIONES INCLUYEN UN NÚCLEO COMPRENDE ESTRÓGENOS CONJUGADOS Y A LO MENOS UNA COBERTURA QUE COMPRENDE BAZEDOXIFENO O UNA SAL DE ELLOS.
PA20068684501A 2005-06-29 2006-06-29 Formulaciones de estrogenos conjugados y bazedoxifeno PA8684501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69488905P 2005-06-29 2005-06-29

Publications (1)

Publication Number Publication Date
PA8684501A1 true PA8684501A1 (es) 2007-01-17

Family

ID=37401610

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20068684501A PA8684501A1 (es) 2005-06-29 2006-06-29 Formulaciones de estrogenos conjugados y bazedoxifeno

Country Status (19)

Country Link
US (1) US20070003623A1 (es)
EP (1) EP1898888A2 (es)
JP (1) JP2008545012A (es)
KR (1) KR20080031037A (es)
CN (1) CN101252921A (es)
AR (1) AR054806A1 (es)
AU (1) AU2006263638A1 (es)
BR (1) BRPI0612586A2 (es)
CA (1) CA2613102A1 (es)
CR (1) CR9597A (es)
EC (1) ECSP078057A (es)
IL (1) IL188223A0 (es)
NI (1) NI200700331A (es)
NO (1) NO20080002L (es)
PA (1) PA8684501A1 (es)
PE (1) PE20070188A1 (es)
RU (1) RU2395286C2 (es)
TW (1) TW200738283A (es)
WO (1) WO2007002823A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1942177B (zh) * 2004-04-08 2011-05-25 惠氏公司 醋酸巴泽多昔芬固体分散剂型
CA2670544A1 (en) * 2006-11-29 2008-06-05 Wyeth Estrogen/ serm and estrogen/ progestin bi-layer tablets
PE20081632A1 (es) * 2007-01-12 2008-12-10 Wyeth Corp Composiciones de tableta en tableta
PE20090100A1 (es) * 2007-03-30 2009-02-26 Wyeth Corp Metodos de separacion y deteccion de acetato de bacedoxifeno en composiciones farmaceuticas
WO2011056532A2 (en) * 2009-10-27 2011-05-12 Wyeth Llc Bazedoxifene formulations with antioxidants
CA2796494A1 (en) * 2010-04-20 2011-10-27 Cipla Limited Pharmaceutical composition
US8615061B2 (en) * 2010-07-29 2013-12-24 Entropic Communications, Inc. Method and apparatus for cross polarization and cross satellite interference cancellation
CA2835845C (en) * 2011-05-13 2020-07-28 Emotional Brain B.V. Drug delivery system
CN104013630B (zh) * 2014-05-23 2018-08-21 合肥九研医药科技开发有限公司 一种复方醋酸巴多昔芬雌激素组合物
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
WO2018182205A1 (ko) * 2017-03-30 2018-10-04 한미약품 주식회사 바제독시펜 아세테이트를 함유하는 안정화된 약제학적 조성물
TWI801561B (zh) * 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) * 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2565115A (en) * 1948-10-28 1951-08-21 Squibb & Sons Inc Method of obtaining a conjugated estrogen preparation
US2720483A (en) * 1951-02-21 1955-10-11 Olin Mathieson Method of obtaining a conjugatedestrogen preparation
US5210081A (en) * 1992-02-26 1993-05-11 American Home Products Corporation Alkali metal 8,9-dehydroestrone sulfate esters
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
TWI359015B (en) * 1999-07-06 2012-03-01 Endorech Inc Pharmaceutical composition for treatment or preve
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
WO2003105834A1 (en) * 2002-06-13 2003-12-24 Wyeth Bazedoxifene treatment regimens
AU2005233133A1 (en) * 2004-04-07 2005-10-27 Wyeth Crystalline polymorph of a bazedoxifene acetate
RU2006132352A (ru) * 2004-04-07 2008-05-20 Вайет (Us) Кристаллическая полиморфная форма базедоксифен ацетата
CN1942177B (zh) * 2004-04-08 2011-05-25 惠氏公司 醋酸巴泽多昔芬固体分散剂型
KR20060134146A (ko) * 2004-04-08 2006-12-27 와이어쓰 선택적 에스트로겐 수용체 모듈레이터로서의 바제독시펜아스코르베이트

Also Published As

Publication number Publication date
US20070003623A1 (en) 2007-01-04
RU2007148071A (ru) 2009-08-10
IL188223A0 (en) 2008-03-20
CA2613102A1 (en) 2007-01-04
WO2007002823A2 (en) 2007-01-04
CN101252921A (zh) 2008-08-27
JP2008545012A (ja) 2008-12-11
EP1898888A2 (en) 2008-03-19
KR20080031037A (ko) 2008-04-07
PE20070188A1 (es) 2007-03-16
NO20080002L (no) 2008-03-12
TW200738283A (en) 2007-10-16
CR9597A (es) 2008-03-06
ECSP078057A (es) 2008-01-23
RU2395286C2 (ru) 2010-07-27
WO2007002823A3 (en) 2007-08-09
AR054806A1 (es) 2007-07-18
NI200700331A (es) 2009-02-16
BRPI0612586A2 (pt) 2010-11-23
AU2006263638A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
ECSP078057A (es) Formulaciones de estrógenos conjugados y bazedoxifeno
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
CL2017001847A1 (es) Una formulación sólida de dosificación farmacéutica
WO2007016563A3 (en) Alcohol resistant pharmaceutical formulations
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
BRPI0418330A (pt) composições sólidas de drogas de solubilidade baixa e poloxámeros
NO20076687L (no) Oral doseringsform
CR11548A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
CR10454A (es) Composiciones farmaceuticas novedosas de baja dosis que comprenden nimesulida , preparacion y uso de las mismas
GT200500357A (es) Indazoles substituidos, composicones que los comprenden, procedimiento de su preparacion y utilizacion
ECSP066481A (es) Formulaciones que contienen cobre
MEP10209A (en) Stable emulsion composition
SV2003001082A (es) Microcapsulas para la proteccion frente al mal aliento
TW200730190A (en) New combination to treat liver fibrosis
BRPI0608287A2 (pt) agente endoparasiticida
GT200400183A (es) Formas de dosificacion de azitromicina con efectos secundarios reducidos
ATE409032T1 (de) Orodispersible pharmazeutische zusammensetzung einer antithrombotischen verbindung
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
ITMI20052077A1 (it) Agente batteriostatica e-o battericida per preparazioni cosmetiche e-o dermofarmaceutiche e preparazioni contenenti questo agente
BRPI0516511A (pt) compostos orgánicos